Pulmonary and cardiac drugs: clinically relevant interactions by Olschewski, H. et al.
Main topic
Herz 2019 · 44:517–521
https://doi.org/10.1007/s00059-019-4834-3
Published online: 11 July 2019
© The Author(s) 2019
H. Olschewski1 · M. Canepa2 · G. Kovacs1
1 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
2 Cardiovascular Unit, Department of Internal Medicine, University of Genova, Genova, Italy
Pulmonary and cardiac drugs:
clinically relevant interactions
Chronic heart disease and lung disease
are both very common among people
around 70 years of age. The most com-
mon single diagnosis in the former group
is chronic heart failure and in the lat-
ter, chronic obstructive pulmonary dis-
ease (COPD). According to the Global
Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines, congestive
heart failure is among themost important
differential diagnoses of COPD [1] and
vice versa. In patients with COPD, heart
disease is associated with a poor progno-
sis [2, 3] and in patients with congestive
heart failure, COPDis likewise associated
with a poor prognosis [4]. Indeed, many
patients suffer from both heart failure
and COPD.
Overlap of heart and lung
disease
According to the prospective ECLIPSE
COPD cohort, nearly 10% of patients
in the study had a known diagnosis
of chronic heart failure and more than
25% had known “heart trouble” [2].
In a large NHS cohort from the UK
with over 31,000 COPD patients and
150,000 matched controls, 17% of the
COPD patients suffered from heart
failure and 29% from ischemic heart
disease [3]. These numbers, although
impressive, may still underestimate the
problem. In The Netherlands, a cohort
of about 400 COPD patients with no
known heart disease underwent thor-
ough multidisciplinary examinations in
a specialized clinic. It was found that,
based on echocardiography, 10% suf-
fered from heart failure with reduced
ejection fraction (HFrEF) and another
10% from heart failure with preserved
ejection fraction (HFpEF; [5]). By far
the highest rates of pathologic findings
were found in patients over 75 years of
age, both in males (mostly HFrEF) and
females (mostly HFpEF). This suggests
that at least 30% of COPD patients suffer
fromconcomitant heart failure. And vice
versa, whenwe look into large congestive
heart failure cohorts, around 30% also
suffer from COPD [4, 6, 7]. This means
that the elderly population in developed
countries presents with a broad overlap
of congestive heart failure and COPD.
There have been several approaches to
explain these strong associations, rang-
ing from shared risk factors like smok-
ing, to shared pathologic mechanisms
like systemic inflammation, to shared
genetic factors. The most comprehen-
sive concept, however, was delivered by
an American Thoracic Society (ATS)/
EuropeanRespiratorySociety (ERS)Task
Force report, interpreting COPD “as the
pulmonary component of a chronicmul-
timorbidity.” This concept explains why
COPD is associated with many common
risk factors, such as smoking, pollution,
ageing, inactivity, and diet [8]. This also
implies that COPD and congestive heart
failure are not only very common in the
adult populationbut also often combined
in a single subject, i.e., COPDcanbe con-
sideredasariskfactorforcongestiveheart
failure and vice versa. In addition, the
Copenhagen City Heart Study showed
that COPD also represents a strong risk
factor for atrial fibrillation and a mod-
erate risk factor for systemic arterial hy-
pertension [9]. This was confirmed in
the most recent large NHS cohort [3].
Beta-adrenergic receptor:
important pharmacologic
target for congestive heart
failure and COPD
In congestive heart failure patients, beta-
blockers are one of the most important
therapeutic options because they signifi-
cantly improve morbidity and mortality
[10]. By contrast, COPD patients profit
frombeta-sympathomimetics, drugs that
have been shown to improve lung func-
tion, dyspnea, and quality of life [11].
Thismaysoundlikeacontradiction: How
should we then treat patients who suffer
from both COPD and congestive heart
failure?
For COPDpatients, the GOLDguide-
lines [11] and the ERS recommendations
[12] provide a clear statement: “Comor-
bidities should be treated as if the patient
did not have COPD.”
In cases of obstructive lung diseases,
beta-sympathomimetics (LABA) are ap-
proved for COPD and asthma and they
are recommended by the current guide-
lines for COPD [13] and asthma [14]
although there is no evidence for a ben-
eficial effect on mortality. Most of the
evidence has been generated for combi-
nation treatments: for asthma with in-
haled corticosteroids (ICS-LABA), and
for COPD with long-acting muscarinic
antagonists (LAMA-LABA). According
to the GOLD and the ERS guidelines,
these medications can be prescribed for
symptomatic COPD patients even if sig-
nificant heart disease is present.
In cases of congestive heart failure as
a comorbidity of COPD, the GOLD/ERS
recommendation [11, 12] means that
patients with an indication for a beta-
blocker should indeed receive a beta-
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Fig. 18 Beta receptors, theirmain function in cardiovascular andpulmonary physiology, and the
most important beta-blockers for clinical use
blocker. According to the current guide-
lines for acute and chronic heart failure
[10] and the Global Initiative for Asthma
(GINA) guidelines for asthma [14], even
asthma is not an absolute contraindica-
tion for beta-blockers, despite reports
of adverse effects from the 1980s and
1990s with mostly unselective beta-
blockers at high initial doses in patients
with severe asthma. For patients with
ischemic heart disease [15, 16] and with
heart failure [17], beta-blocker use was
associated with a significant beneficial
effect on mortality. This was not only
true for the whole study population but
particularly for the subgroup of patients
with concomitant COPD. In addition,
beta-blockers are important medica-
tions for controlling atrial fibrillation
and systemic hypertension.
Receptor specificity and route
of application
Beta-blockers
Cardiovascular diseases are the most
frequent and important comorbidities of
COPD and include ischemic heart dis-
ease, congestive heart failure, and atrial
fibrillation. For these diseases there are
clear indications for beta-blockers. In
COPD patients, beta1 selective beta-
blockers are considered to be advanta-
geous, although there are also data for
the unselective beta1/beta2 adrenergic
blocker carvedilol suggesting a good
tolerability in COPD patients [18]. Still,
a potential problem is the large over-
lap between COPD and asthma. Up
to 30% of COPD patients may suffer
from asthma as a comorbidity [19] and
asthma patients may develop adverse ef-
fects from nonselective beta-blockers. If
the beta1/beta2 effect of propranolol was
1, bisoprolol would have a ratio of 103
and nebivolol of 321 [20]. Nebivolol is
a substance that has strong beta1-block-
ing properties, virtually no effect on the
beta2 receptor and at the same time is
a beta3 receptor agonist (. Fig. 1). This
profile might be particularly advanta-
geous for patients with heart disease and
COPD with an asthmatic component
and/or pulmonary arterial vasoconstric-
tion. However, because there was no
significant beneficial effect of nebivolol
on mortality in a recent study with Asian
patients [21], nebivolol was not recom-




function and dyspnea by means of their
bronchodilating properties via activation
of the beta2 receptor of the bronchial
smooth muscle cells (. Fig. 1). Princi-
pally they can be delivered systemically
or via the inhaled route. Unfortunately,
none of the available beta2 agonists is
highly selective for the beta2 receptor and
they all may cause beta1 agonistic effects
like tachycardia and increasedoxygende-
mand of the heart. Therefore, systemic
application, which is associated with
many more cardiac side effects than in-
haled application, is not recommended.
In addition, the approved substances
have different pharmacologic profiles.
The short-acting beta2 agonists (SABA),
like salbutamol and fenoterol, were the
first available substances, followed by
long-acting beta2 agonists (LABA) like
salmeterol for twice daily use and ultra-
long-acting substances like indacaterol,
olodaterol, and vilanterol for once daily
use. As a rule, immediate onset of bron-
chodilatation is associated with a short
duration, and a slow onset with a long
duration of the drug. However, there is
one exception to the rule: Formoterol has
both a rapid onset and a long duration of
bronchodilation. This is why the GINA
guidelines recommend only formoterol
as an on-demand combination drug in
Step 1 and Steps 3–5 of asthma therapy
[14]. Although there is no head-to-head
comparison, LABA are considered supe-
rior to SABA for chronic stable asthma
and COPD disease, because they are less





When the patient is treated with an
unselective beta-blocker, a concomitant
LABA therapy may ameliorate any bron-
choconstrictive effects. And vice versa,
any adverse effects of the LABA on the
heart will be ameliorated by the beta-
blocker. When the patient is treated
with a beta1 selective beta-blocker, even
a high-dose beta-blocker will not cause
bronchoconstriction, because the beta
receptors are stimulated by the LABA.
And vice versa, as the LABA is delivered
via the inhaled route, it will not cause
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major cardiac side effects and any minor
side effects will be ameliorated by the
beta-blocker.
In summary there is an excellent
rationale for treating patients suffering
from heart failure and COPD with both
a beta1 selective beta-blocker and an




Aspirin is a mainstay of secondary pre-
vention in ischemic heart disease. In
addition, it has a significant preventive
role for recurrent venous thromboem-
bolism [22]. Aspirin increases the risk of
bleeding and this may affect COPD pa-
tients more than other patients owing
to coughing, osteoporosis, and fragile
small vessels. In addition, COPD may
be associated with asthma and among
these patients some will be sensitive to
aspirin and other nonsteroidal anti-in-
flammatory drugs (NSAIDs). This spe-
cial asthma phenotype is often associ-
ated with “late-onset asthma” and nasal
polyposis. However, since the aspirin for
ischemic diseases is taken on a daily ba-
sis, there will be a desensitization of the
asthma mechanism and adverse effects
on the airways are very unlikely.
Oral anticoagulants are often indi-
cated in ischemic and congestive heart
disease and in atrial fibrillation. Pa-
tients with COPD may be more prone
to bleeding complications than patients
withoutCOPD.This isveryobvious inthe
skin but also affects the abdominal mus-
cles and other organs. Severe coughing
in combination with osteoporosis rep-
resents a strong risk factor for rib and
vertebral fractures. In such cases, anti-
coagulation may cause significant com-
plications.
Amiodarone is still the most potent
anti-arrhythmic drug and is used for ven-
tricularandsupraventriculararrhythmia.
Unfortunately, there is a dose-dependent
toxicity that can affect many organs. In
the lung it causes alveolitis, which is as-
sociated with worsening of pulmonary
gas exchange and severe hypoxemia. Be-
cause of the extremely long half-life of
amiodarone, itmaytakemanyweeksafter
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Abstract
Chronic heart and lung diseases are very
common in the elderly population. The
combination of chronic heart failure and
chronic obstructive pulmonary disease
(COPD) is also common and, according to
current guidelines, these patients should be
treated for both diseases. In patients with
heart failure, beta-blockers are very important
drugs because their use is associated
with significantly improved morbidity and
mortality. These beneficial effects were
documented in patients with and without
COPD, although theoretically there is a
risk for bronchoconstriction, particularly
with non-beta1 selective blockers. In COPD
patients, long-acting sympathomimetics
(LABA) improve lung function, dyspnea,
and quality of life and their combination
with a beta-blocker makes sense from
a pharmacological and a clinical point of
view, because any potential arrhythmogenic
effects of the LABA will be ameliorated by
the beta-blocker. Inhaled tiotropium, a long-
acting muscarinic antagonist (LAMA), has
been extensively investigated and no safety
concerns were reported in terms of cardiac
adverse effects. The same applies for the
other approved LAMA preparations and
LAMA-LABA combinations. Severe COPD
causes air-trappingwith increasing pressures
in the thorax, leading to limitations in blood
return into the thorax from the periphery of
the body. This causes a decrease in stroke
volume and cardiac index and is associated
with dyspnea. All these adverse effects can
be ameliorated by potent anti-obstructive
therapy as recently shown by means of a
LABA-LAMA combination.
Keywords
Heart failure · Chronic obstructive pulmo-
nary disease · Beta-adrenergic blockers ·
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Lungen- und Herzmedikamente: klinisch relevante
Wechselwirkungen
Zusammenfassung
Chronische Herz- und Lungenerkrankungen
sind in der älteren Bevölkerung sehr
verbreitet. Die Kombination von chronischer
Herzinsuffizienz und chronischer obstruktiver
Lungenerkrankung (COPD) ist ebenfalls
häufig, und diese Patienten sollten, gemäß
aktuellen Leitlinien, hinsichtlich beider Er-
krankungen behandelt werden. Bei Patienten
mit Herzinsuffizienz spielen Betablocker eine
sehr wichtige Rolle, weil ihre Anwendung
mit einer signifikant verbesserten Morbidität
und Mortalität einhergeht. Diese günstigen
Auswirkungen wurden sowohl bei Patienten
mit als auch bei Patienten ohne COPD doku-
mentiert, obwohl theoretisch das Risiko einer
Bronchokonstriktion besteht, insbesondere
bei nicht-beta1-selektiven Blockern. Bei
COPD-Patienten führen langwirksame Sym-
pathomimetika (LABA) zu einer Verbesserung
in Bezug auf Lungenfunktion, Dyspnoe und
Lebensqualität, und ihre Kombination mit
einem Betablocker ist aus pharmakologischer
und klinischer Sicht sinnvoll, da potenzielle
arrhythmogene Wirkungen der LABA günstig
durch den Betablocker beeinflusst werden.
Inhalierbares Tiotropium, ein langwirksamer
Muskarinantagonist (LAMA), wurde umfas-
send untersucht, es bestätigten sich jedoch
keine Sicherheitsbedenken hinsichtlich
kardialer Nebenwirkungen. Gleiches gilt
für die anderen zugelassenen LAMA-
Präparate und LAMA-LABA-Kombinationen.
Eine schwergradige COPD verursacht eine
Lungenüberblähung mit ansteigendem
Druck im Thorax, was zur Beeinträchtigung
des Blutrückflusses aus der Peripherie des
Körpers in den Thorax führt. Dies verursacht
eine Abnahme des Schlagvolumens und des
Herzindex und geht mit Dyspnoe einher. All
diese Nebenwirkungen können durch eine
potente antiobstruktive Therapie günstig




Herzinsuffizienz · Chronische obstruktive
Lungenerkrankung · Betaadrenerge Blocker ·
Sympathomimetische Medikamente ·
Medikamentennebenwirkungen
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cessation of amiodarone treatment until
the alveolitis improves. The risk of life-
threatening complications of alveolitis is
increased in subjects with pre-existing
lung disease like COPD.
Angiotensin-converting enzyme
(ACE) inhibitors (ACEi) remain impor-
tant drugs for the treatment of congestive
heart failure. However, they may fre-
quently cause chronic cough and rarely
they may cause angioedema. In COPD
patients, cough is common and ACEi-
induced cough may be mistaken for
COPD or asthma exacerbations. This
may explain why in hospitalized patients
with concomitant COPD, compared to
those without COPD, ACEi were less
frequently applied [23].
Potential interactions between
COPD medication and heart
disease
Long-acting muscarinic antagonists
(LAMA) have been one of the most
important therapy options for COPD
since the first drug of this class was
approved in 2008. Since then, four
substances—tiotropium, glycopyrro-
nium, aclidinium bromide and ume-
clidinium—have been approved for in-
haled use in COPD. Before 2008, only
ipratropium, a short-acting muscarinic
antagonist (SAMA), was available for
inhaled use. A meta-analysis suggested
significant adverse cardiovascular out-
comes forstudiescomparing ipratropium
with placebo and for all studies where
either ipratropium of tiotropium was
compared with placebo [24]. However,
a randomized controlled study with
tiotropium, delivered by the HandiHaler
device, showed significant beneficial ef-
fects of tiotropium on adverse cardiac
events [25]. After introduction of the
Respimat inhaler for tiotropium, there
were again safety concerns because of
reports of adverse cardiovascular out-
comes as compared with the tiotropium
HandiHaler. However, a large prospec-
tive randomized controlled study with
the Respimat device showed no evidence
for increased cardiovascular adverse ef-
fects [26]. In conclusion, LAMA are
considered safe in cardiac patients, al-
though high-quality evidence for safety
from large databases is only available for
tiotropium.
Theophylline (dimethylxanthine) has
been used for airway obstruction since
1922. Xanthines are known to inhibit
several phosphodiesterases (PDE-3, 4,
5, 7, 9) that are present in bronchial
smooth muscle cells and inflammatory
cells. This has bronchodilatory and anti-
inflammatoryeffects [27]. However, xan-
thines also inhibit adenosine receptors
(AR-A1, A2A, A2B, A3), which may
cause cardiac side effects. Among the
different xanthine drugs, doxophylline
has strong PDE inhibitory effects and
modest adenosine receptor effects, which
translates into clinical superiority over
other xanthines [28]. According to cur-
rent guidelines, xanthines are not consid-
ered as first-line medications for COPD
or asthma. However, in patients who
do not tolerate beta agonists, they may
still have a place, particularly in younger
adults with no cardiac disease. A newly
developed PDE inhibitor (roflumilast) is
recommended for patients with severe
COPD with productive cough who are
not underweight [13]. The drug often
causes diarrhea, nausea, and weight loss.
This profile might be particularly advan-
tageous to patients at risk for chronic
heart disease due to over-nutrition.
Oral corticosteroids (OCS) should
be avoided in the chronic treatment
of COPD and asthma; however, some
patients respondwith frequent exacerba-
tions after cessation of OCS. Interleukin-
5 inhibitors have been approved to avoid
or reduce OCS but only in asthma and
not in COPD. During acute exacerba-
tions of COPD and asthma, OCS with
0.5mg/kg prednisolone for 5 days [29] is
recommended because this therapy leads
to relief of obstruction and symptoms
and shortens the hospitalization [11].
Unfortunately, OCS are associated with
a multitude of adverse events among
which venous thromboembolism is of
special interest for COPD patients be-
cause it may mimic COPD exacerbation
[30] and is more difficult to diagnose
than in patients without structural lung
disease. It is also of interest for chronic
heart failure because these patients per
se have a significantly increased risk for
venous thromboembolism.
Chronic cor pulmonale
Pulmonary disease may affect the heart,
and the most obvious consequence
of chronic lung disease on the heart is
chronic cor pulmonale. This observation
was made by ancient pathologists and
defined as the presence of a dilated right
ventricle in a patient without obvious
left heart disease. However, the MESA
COPD study, by means of systematic
magnetic resonance imaging (MRI) and
pulmonary function test (PFT), found
that the right ventricular volume in sta-
ble COPD patients was smaller by about
8ml compared with healthy matched
controls [31]. There was a highly signif-
icant correlation between the degree of
airway obstruction and the reduction of
the right ventricular volume, and there
was a highly significant correlation be-
tween the amount of emphysema and the
reduction in right ventricular volume.
This led to the hypothesis that the posi-
tive intrathoracic pressure in obstructive
lung disease prevents blood flow into
the thorax and causes underfilling of the
heart.
A recent interventional study demon-
strated that this hypothesis was true and
that the mechanism was reversible. By
meansofapotentantiobstructivetherapy,
using an inhaled LABA/LAMA combi-
nation for 2 weeks in patients with severe
COPD with no cardiac disease, the right
ventricular volume increased by about
7ml, along with a significant increase in
stroke volume and cardiac output [32].
These changes were due to a significant
reduction in the pulmonary residual vol-
ume and altogether resulted in a highly
significant beneficial effect on dyspnea
and quality of life. This suggests that air
trapping, due to obstructive lung disease
causes intrathoracicpressure increase, re-
sulting in cardiac underfilling and hemo-
dynamic stress and that these pathologic
findings can be reversed by potent bron-
chodilatory therapy. However, such ef-
fects may be much less impressive if the
patients suffer from some degree of left
heart disease [33].
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Conclusion
In conclusion, the combination of
chronic heart and lung diseases is
very common in the elderly popula-
tion. Patients should be treated for
both diseases. Beta-blockers are very
important drugs because their use is
associated with significantly improved
morbidity andmortality, and their
combination with inhaled long-acting
sympathomimetics makes sense from
a pharmacological and a clinical point
of view. There are numerous potential
effects of heart medications on the
diseased lung and of lungmedications
on the diseased heart. However, in most
instances, such medication is justified,
just as in cases where the other disease
is not present.
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